- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02855372
Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)
It is commonly accepted that the characteristics of the organ donor impact on the future post transplant. In lung transplantation (LP), the defining characteristics of the "ideal" donor includes an age less than 55 years. However, before the pulmonary graft shortage with a corresponding mortality still too high waiting list, the lung graft acceptance criteria were reassessed permitting criteria "extension" ( "marginal" graft). And were grafted, depending on the urgency and accessibility problems in the registry of potential candidate, organs from donors aged 55 and older with quite comparable to those obtained from younger donors . Nevertheless, it is common practice that the grafts from older donors are more readily allocated to older candidates and the most severe, as many confounding factors to assess the real impact of donor age on post-transplant evolution on small cohorts.
The main goal of this study is to compare the survival of lung transplant patients depending on the age difference between donor and recipient.
The study will be conducted from a broad national cohort of lung transplant patients registered in COLT ( Lung Transplantation COhort). Established in September 2009, promoted by the University Hospital of Nantes, COLT involves 11 lung transplant centers authorized on French territory. It provides a standardized common longitudinal monitoring of the recipient from his transplant. Currently more than 1,000 patients included in this study are transplanted.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Urielle DESALBRES
- Phone Number: 04 91 38 20 61
- Email: urielle.desalbres@ap-hm.fr
Study Locations
-
-
-
Marseille Cedex 01, France, 13915
- Assistance Publique Hôpitaux de Marseille, Hôpital Nord
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female adult patients, included in COLT cohort, thus having given a signed written consent
- Who received a lung transplant
Exclusion Criteria:
- Lung transplanted patients in a context of national priority
- Lung transplanted patients who died within 3 months after the surgery
- Patients for whom it is a second lung transplantation
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lung transplanted patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Age difference in years between donor and recipient
Time Frame: 1 day
|
The age difference will then be able to define two groups of patients:
|
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2015-39
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Transplantation
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Emory UniversityCompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Heart-Lung TransplantationUnited States
-
Astellas Pharma IncCompletedHeart Transplantation | Lung Transplantation | Pancreas (Including SPK) TransplantationFrance, United Kingdom, Taiwan, Belgium, Italy, Austria
-
Hannover Medical SchoolUnknownExercise Training | Lung Transplantation | Psychotherapy | Heart-Lung Transplantation | "Rehabilitation"Germany
-
University of AlbertaNatera, Inc.; One LambdaRecruiting
-
Universidad Complutense de MadridHospital Universitario 12 de OctubreRecruiting
-
KU LeuvenCompleted
-
Hopital FochCompleted
-
Emory UniversityTerminated
-
Hannover Medical SchoolCorscience, Inc.CompletedLung TransplantationGermany
Clinical Trials on Lung transplantation
-
Hospices Civils de LyonRecruiting
-
Northwestern UniversityRecruitingLung Cancer | Lung Transplant | Bilateral CancerUnited States
-
University Health Network, TorontoMedical University of Vienna; University of California, San Francisco; Vanderbilt... and other collaboratorsRecruitingLung Transplant | Organ PreservationUnited States, Austria, Canada, Spain
-
Aylin Seylam KüşümlerKoşuyolu Yüksek İhtisas Training and Research HospitalActive, not recruiting
-
Rigshospitalet, DenmarkUnknown
-
Policlinico HospitalCompletedCystic FibrosisItaly
-
Kyoto University, Graduate School of MedicineMinistry of Health, Labour and Welfare, JapanUnknown
-
Hospices Civils de LyonCompletedCystic Fibrosis | Pulmonary FailureFrance
-
Hopital FochCompletedTransplantation, Lung | Transplant Dysfunction
-
Hopital FochCompletedPulmonary Insufficiency | MucoviscidosisFrance